Introduction of Second-line Treatment for HCC Patients to Drive Global HCC Market

Published Date : Apr 11, 2016

Albany, New York, April 11, 2016 – has recently added a new research report to its vast repository. The research report, titled “OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis And Forecasts To 2024,” analyzes the growth opportunities of the hepatocellular carcinoma market. The research report has been compiled using primary and secondary research methodologies. To explain the precise state of the market, the researchers have used Porter’s five forces reports. This helps them in assessing the bargaining power of customers, the threat of new entrants, the intensity of competitive rivalry, the bargaining power of suppliers, and the threat of substitute products or services. Additionally, the report also examines the strengths, weaknesses, opportunities, and threats impacting the segments of the global hepatocellular carcinoma market by using SWOT reports. The thoroughly researched document contains an reports of the historical data and compares it with the present market situation to chart the expected trajectory of this market for the coming years.

Hepatocellular carcinoma or HCC is a type of a liver cancer and is known to be the second most common cause of death that is related to cancer amongst men and the sixth leading cause amongst women. This form of cancer accounts for nearly 85% of liver cancer cases. The progression of HCC is determined on its stage at the time of diagnosis. Unfortunately, the majority of HCC patients progress to advanced states of the diseases, while only early-stage patients are able to receive treatment with liver transplantation, surgical resection, and ablative therapies.

For Sample Copy, click here:

The research report attempts to answer questions pertaining to Nexavar, which is expected to be the only possible treatment for patients with advanced HCC. The drugs that will make the biggest impact in the coming years on the market and the strategies being developed by pharmaceutical and healthcare companies to overcome the high rate of failure in clinical trials are analyzed as well. The research report also states that the primary growth drivers of the global HCC market will be the increasing usage of second-line treatment for patients with advanced HCC. The overall market will also be supported by the growing number of geriatrics, who are prone to HCC. The only restraint on the overall HCC market will be the introduction of generic sorafenib. However, the unmet demand from several patients suffering from HCC will continue to offer huge opportunities for growth of this market.

The research report lists and assesses the impact of certain drugs that are in the pipeline such as multi kinase inhibitors, Cyramza, Lenvima, ThermoDox, Stivarga, Cometriq, Tivantinib, Pexa-Vec, Livatag, Pegargiminase, and Peretinoin.  The research report aims to help the readers design and develop in-licensing and out-licensing strategies. By understanding the key trends that are likely to shape the global HCC therapeutics market, the research report provides its readers a basic framework for decision-making.

To order report Call Toll Free: 866-997-4948 or send an email on